ProQR Therapeutics (PRQR) Common Equity (2012 - 2026)

ProQR Therapeutics (PRQR) has reported Common Equity for 15 consecutive years, with $42.8 million the latest figure, recorded in Q1 2026.

• Quarterly Common Equity fell 52.37% year-over-year to $42.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.8 million (down 52.37% YoY) and the FY2025 annual result came in at $56.2 million, down 44.25% from the prior year.
• Common Equity eased to $42.8 million in Q1 2026 per PRQR's latest filing, from $56.2 million in the prior quarter.
• Over the last five years, Common Equity for PRQR reached as high as $115.4 million in Q1 2022 and fell as low as $28.4 million in Q3 2024.
• A 5-year average of $66.6 million and a median of $64.9 million in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2025 — Common Equity jumped 128.45% — and 2026, when it slumped 52.37%.
• Year by year, Common Equity stood at $75.9 million in 2022, then tumbled by 37.93% to $47.1 million in 2023, then surged by 113.96% to $100.8 million in 2024, then slumped by 44.25% to $56.2 million in 2025, then dropped by 23.85% to $42.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $42.8 million, $56.2 million, and $64.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.